Answers are grounded in this paper and cite their sources.
Phase 2 trial shows omadacycline monotherapy improves outcomes in nontuberculous mycobacterial lung infection, indicating potential efficacy.
Results consistently favored omadacycline monotherapy over placebo across several endpoints in NTM-PD caused by M. abscessus. Omadacycline was well tolerated; nausea was the most frequent TEAE. Further investigations are warranted.
No takes yet. Share an insight, caveat, or question.
Winthrop et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: